EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ5676 is a highly selective DOT1L histone methyltransferase inhibitor with an IC50 of 0.8 nM and a Ki of 80 pM, demonstrating >37,000-fold selectivity over other methyltransferases (APExBIO). It competitively inhibits DOT1L by binding the S-adenosyl methionine (SAM) pocket, leading to potent H3K79 methylation inhibition and downregulation of MLL-fusion target genes. In vivo, EPZ5676 induces complete tumor regression in MV4-11 xenograft models without significant toxicity. The compound is optimized for biochemical and cellular assays, serving as a benchmark antiproliferative agent in MLL-rearranged leukemia research (Kim et al., 2018).

Biological Rationale

DOT1L (Disruptor of Telomeric Silencing 1-Like) is the only known methyltransferase for histone H3 lysine 79 (H3K79). H3K79 methylation is essential for regulating gene expression in both normal hematopoiesis and leukemogenesis. In mixed lineage leukemia (MLL)-rearranged leukemias, aberrant recruitment of DOT1L by MLL fusion proteins causes persistent H3K79 methylation, leading to dysregulated activation of oncogenic transcriptional programs. Targeting DOT1L thus represents a rational therapeutic strategy for selectively inhibiting MLL fusion-driven leukemias (histone-h2a.com). Inhibitors such as EPZ5676 directly abrogate this aberrant epigenetic signaling, providing a molecularly targeted approach distinct from conventional cytotoxic chemotherapies.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 functions as a competitive inhibitor of the SAM-binding site on DOT1L. By occupying this site, it prevents the transfer of methyl groups to H3K79, resulting in a loss of methylation at this residue. Structural analyses reveal that EPZ5676 induces conformational changes in DOT1L, opening a hydrophobic pocket beyond the SAM amino acid moiety. This mechanism underpins the compound's high selectivity, enabling >37,000-fold discrimination over related methyltransferases such as CARM1, EHMT1/2, and PRMT family enzymes (APExBIO). In cellular contexts, EPZ5676 exposure leads to rapid, concentration-dependent reductions in H3K79 methylation, followed by downregulation of MLL-fusion gene targets and cytotoxic effects in MLL-rearranged leukemia cells (carmofur.com—this article extends mechanistic precision to practical research workflows).

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L activity with an IC50 of 0.8 nM and a Ki of 80 pM under standard enzyme assay conditions (25°C, Tris buffer, pH 7.5) (APExBIO).
• Exhibits >37,000-fold selectivity over CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1 in biochemical assays (APExBIO).
• Displays antiproliferative activity in MV4-11 leukemia cells with an IC50 of 3.5 nM after 4–7 days of continuous exposure (APExBIO).
• In nude rat MV4-11 xenograft models, intravenous administration (35–70 mg/kg/day for 21 days) achieves complete tumor regression without significant toxicity or weight loss (APExBIO).
• Inhibition of H3K79 methylation leads to downregulation of MLL-fusion target genes (e.g., HOXA9, MEIS1) and induction of apoptosis in MLL-rearranged leukemia cells (Kim et al., 2018).

Applications, Limits & Misconceptions

EPZ5676 is primarily employed in biochemical enzyme inhibition assays, cell proliferation studies, and in vivo preclinical models of MLL-rearranged leukemia. Its high specificity makes it ideal for dissecting DOT1L-driven epigenetic mechanisms without off-target methyltransferase inhibition. Notably, recent research explores its potential in fibrotic disease models and other epigenetic contexts (histone-h2a.com; this article updates the discussion by focusing on quantitative selectivity data and leukemia-specific benchmarks).

Common Pitfalls or Misconceptions

• EPZ5676 does not inhibit histone demethylases or DNA methyltransferases; it is selective for DOT1L.
• It is ineffective in cancers without dysregulated H3K79 methylation or MLL rearrangements.
• Water insolubility limits its use in purely aqueous systems without appropriate cosolvents (DMSO or ethanol required).
• Long-term storage of solutions at room temperature results in degradation; cold storage is essential.
• Not suitable for targeting Wnt/β-catenin-driven stemness, as shown for pan-histone demethylase inhibitors like JIB-04 (Kim et al., 2018).

Workflow Integration & Parameters

EPZ5676 is supplied as a solid (molecular weight: 562.71 Da) by APExBIO (SKU: A4166). Recommended storage is at -20°C; stock solutions in DMSO are stable for several months below -20°C. Compound solubility is ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (with ultrasonic assistance); it is insoluble in water. For cell-based assays, typical working concentrations range from 1 to 100 nM, with treatment durations of 4–7 days for proliferation inhibition. In vivo protocols employ intravenous dosing (35–70 mg/kg/day, 21 days). For further guidance on robust assay set-up and troubleshooting, see 'Scenario-Driven Solutions with DOT1L inhibitor EPZ-5676' (kdm2a.com; this article clarifies quantitative benchmarks and practical storage parameters).

Conclusion & Outlook

EPZ5676 stands as a gold-standard DOT1L inhibitor, enabling rigorous dissection of epigenetic regulation in MLL-rearranged leukemia. Its specificity and robust in vivo efficacy distinguish it from broader epigenetic modulators. Continued research may reveal further applications in non-leukemic disease models, but its current strengths lie in targeted, mechanism-driven cancer research. For detailed product specifications and ordering, refer to the DOT1L inhibitor EPZ-5676 product page at APExBIO.